These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24302197)

  • 21. Vancomycin: The pendulum swings.
    Scheetz MH
    Am J Health Syst Pharm; 2020 May; 77(11):810-811. PubMed ID: 32426842
    [No Abstract]   [Full Text] [Related]  

  • 22. Vancomycin: new dosing and monitoring recommendations for adults.
    Farver DK
    S D Med; 2009 Jul; 62(7):277-9. PubMed ID: 19774795
    [No Abstract]   [Full Text] [Related]  

  • 23. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin Area Under the Curve-guided Dosing and Monitoring: "Is the Juice Worth the Squeeze"?
    Lodise TP; Hall RG; Scheetz MH
    Pharmacotherapy; 2020 Dec; 40(12):1176-1179. PubMed ID: 33368454
    [No Abstract]   [Full Text] [Related]  

  • 25. How to use vancomycin optimally in neonates: remaining questions.
    Jacqz-Aigrain E; Leroux S; Zhao W; van den Anker JN; Sharland M
    Expert Rev Clin Pharmacol; 2015; 8(5):635-48. PubMed ID: 26289222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
    Zelenitsky SA; Ariano RE; McCrae ML; Vercaigne LM
    Clin Infect Dis; 2012 Aug; 55(4):527-33. PubMed ID: 22573855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units.
    Kadambari S; Heath PT; Sharland M; Lewis S; Nichols A; Turner MA
    J Antimicrob Chemother; 2011 Nov; 66(11):2647-50. PubMed ID: 21862473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak M; Lomaestro B; Rotschafer JC; Moellering R; Craig W; Billeter M; Dalovisio JR; Levine DP
    Am J Health Syst Pharm; 2009 Jan; 66(1):82-98. PubMed ID: 19106348
    [No Abstract]   [Full Text] [Related]  

  • 29. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Moving Target-Vancomycin Therapeutic Monitoring.
    Burns AN; Goldman JL
    J Pediatric Infect Dis Soc; 2020 Sep; 9(4):474-478. PubMed ID: 32716487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin levels: to draw or not to draw.
    Creekmore F
    S D J Med; 1998 Jun; 51(6):195-6. PubMed ID: 9646718
    [No Abstract]   [Full Text] [Related]  

  • 32. Vancomycin dosing and monitoring.
    Med Lett Drugs Ther; 2009 Apr; 51(1309):25. PubMed ID: 19343006
    [No Abstract]   [Full Text] [Related]  

  • 33. Validation of two vancomycin nomograms in patients 10 years of age and older.
    Gillon JE; Cassat JE; Di Pentima MC
    J Clin Pharmacol; 2014 Jan; 54(1):35-8. PubMed ID: 24249098
    [No Abstract]   [Full Text] [Related]  

  • 34. Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.
    Elbarbry F
    Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):259-268. PubMed ID: 29260505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children.
    Gordon CL; Thompson C; Carapetis JR; Turnidge J; Kilburn C; Currie BJ
    Pediatr Infect Dis J; 2012 Dec; 31(12):1269-71. PubMed ID: 22828642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy.
    Zasowski EJ; Lodise TP
    J Clin Pharmacol; 2018 Sep; 58(9):1131-1133. PubMed ID: 30024648
    [No Abstract]   [Full Text] [Related]  

  • 37. Barriers and facilitators of appropriate vancomycin use: prescribing context is key.
    Chan JOS; Baysari MT; Carland JE; Sandaradura I; Moran M; Day RO
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1523-1529. PubMed ID: 30056569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD; Goldstein FW
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates.
    Tasa T; Metsvaht T; Kalamees R; Vilo J; Lutsar I
    Ther Drug Monit; 2017 Dec; 39(6):604-613. PubMed ID: 29084032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.